论文部分内容阅读
目的:观察探究恩替卡韦治疗乙型病毒性肝炎失代偿性肝硬化疗效。方法:选取我院2015年8月~2017年8月我院肝病科接诊的64例乙型病毒性肝炎失代偿性肝硬化患者作为研究对象,将其随机分为观察组和对照组各32例,对照组行常规治疗,观察组行恩替卡韦治疗,对比两组患者治疗效果。结果:经治疗后,两组患者肝功能各项指标均有所改善,观察组患者肝功能指标改善情况明显好于对照组,P<0.05;观察组Child-pugh评分明显低于对照组,t=9.797,P<0.05。结论:对乙型病毒性肝炎失代偿性肝硬化患者应用恩替卡韦治疗效果明显,能有效改善患者肝功能各项指标,用药安全有效,该治疗方法有较高的参考价值。
Objective: To investigate the efficacy of entecavir in the treatment of decompensated cirrhosis of patients with hepatitis B virus. Methods: Sixty-four patients with decompensated cirrhosis of hepatitis B from August 2015 to August 2017 in our hospital were enrolled in this study. They were randomly divided into observation group and control group 32 cases in control group were treated routinely, the observation group entecavir treatment, the treatment effect of two groups were compared. Results: After treatment, the indexes of liver function in both groups were improved. The improvement of liver function indexes in the observation group was significantly better than that in the control group, P <0.05. The Child-pugh score in the observation group was significantly lower than that in the control group = 9.797, P <0.05. Conclusion: The treatment of patients with decompensated cirrhosis of hepatitis B with entecavir has obvious curative effect, which can effectively improve various indexes of liver function and is safe and effective. The treatment method has high reference value.